CV/COS Webinar: Applications and Future Directions

At Carevive, we believe that data is a powerful tool that can revolutionize cancer care. In this video, we explore the diverse applications of our data and how it can drive better outcomes for patients and clinicians alike.

One crucial application lies in supporting patient-reported outcome (PRO) measure selection for clinical trial planning. Our real-time data from a standard-of-care population offers contemporary insights into FDA-relevant domains. Unlike historical trial data that can quickly become outdated due to rapidly evolving oncology standards, our data ensures up-to-date and relevant measure selection.

Furthermore, our data serves as a bridge between real-world data and clinical trials. With PRO measures similar in domain coverage and assessment frequency, comparing patient experiences on treatment becomes more comparable, enabling apples-to-apples comparisons for efficacy, safety, and tolerability assessments.

The ability to analyze population-level differences and individual time course changes remotely is yet another valuable aspect of our data. This feature proves instrumental in profiling the impact of care management interventions and predicting risk factors.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…